Blue Water Acquisition Corp.
Completed 2021-09-09- CIK 1817944
- BLUW
- Now CRXT
- IPO 2020-12-16
- $58.7M trust
- 236 filings
Successfully merged with Clarus Therapeutics, Inc. • Now trading as CRXT
- IPO Size
- $57.5M
- raised at the IPO
- Trust
- $58.7M
- as of 2021-06-30
- Current Status
- Completed
- from its latest filing
- IPO Year
- 2020
- year it listed
Filings, by quarter
236 filings over 11 quarters; violet bars carry a milestone
- 20 Q3: 3 filings
- 20 Q4: 18 filings
- 21 Q1: 7 filings
- 21 Q2: 22 filings
- 21 Q3: 44 filings
- 21 Q4: 34 filings
- 22 Q1: 15 filings
- 22 Q2: 52 filings
- 22 Q3: 22 filings
- 22 Q4: 5 filings
- 23 Q1: 14 filings
- S-1 filed 20 Q3
- IPO 20 Q4
- Definitive agreement 21 Q2
- Completed 21 Q3
SPAC Overview
Where it stands on the road from S-1 to merger
Timeline Progress
About
Blue Water Acquisition Corp. is a blank-check company seeking a business combination, with an intended focus on healthcare, particularly life sciences and pharmaceutical services companies.
Investment Focus
Healthcare, Biopharmaceuticals
Geographic Focus
United States, Europe
Key Information
As the filings state it
- IPO Date
- 2020-12-16
- Total Redemptions
- $33.4M
- PIPE
- $25M
- Jurisdiction of Incorporation
- Delaware
- SIC
- 6770
- Completion Date
- 2021-09-09
- Merger Target
- Clarus Therapeutics, Inc.
- SPAC Ticker
- BLUW
- Merged Ticker
- CRXT
Stock Performance
CRXTTrading symbol, and its price at each step since the first trade
| Point | Date | Price | Move |
|---|---|---|---|
| First Trade | 2025-07-31 | $9.93 | |
| 6 Months Post-Merger | 2025-07-31 | $9.98 | 0% |
| 1 Year Post-Merger | 2025-07-31 | $9.98 | 0% |
| 2 Years Post-Merger | 2025-07-31 | $9.98 | 0% |
| Current Price | 2026-09-25 | $10.37 | +4% |
SPAC Team
The banks on its IPO, and the team as the filings describe it
Underwriters
Extended Team Information
The team is led by founder, Chairman and CEO Joseph Hernandez, a healthcare entrepreneur with experience founding or leading eight companies, and CFO Jon Garfield, who has extensive financial leadership experience including in healthcare. The directors bring experience in pharmaceutical and healthcare leadership, commercial operations, life sciences, and legal matters.